In an Israeli first, two women have each been given a 3D printed titanium alloy implant to replace a broken talus (the main connector between the foot and leg). Doctors at Beilinson Hospital in Petah Tikva are confident that both women will soon be walking normally again.
I reported previously on the Namodenoson (CF102) liver cancer treatment from Israel’s Can-Fite. After Phase 2 testing, a supply of CF102 has been manufactured for “compassionate use” on critically ill patients at Rabin Medical Center in Petah Tikva.
Dvir Schnerb was released from hospital two weeks after being critically wounded by a terrorist bomb that killed his sister. A few hours later he received his certification as a volunteer EMT for Magen David Adom. He said he will honor his sister’s memory by working to save lives.
Israel’s MDClone system generates anonymous medical research data from real medical records. Customers include Israeli health companies Maccabi and Clalit and (in the US) Washington University hospital and Intermountain. MDClone has just raised $26 million of funds.
Every year the Israel Cancer Research Fund (ICRF) awards grants to Israeli researchers working to find cures and treatments for cancer. This year its 69 grants of $4.3 million focus on cancer genetics, targeted cancer therapies and immunotherapy. Read about some of the amazing work.
Tuberculosis (TB) kills 1.6 million people a year. Israeli startup Keheala has developed a “low-tech” system whereby Keheala sends SMS reminders to patients in Kenya to take their meds. The patient must respond with an SMS otherwise a Keheala mentor gets involved. Trials were 96% successful.
I reported previously when GE Medical integrated the imaging analysis software from Israel’s DiA into its ultrasound devices. Now, DiA is to provide its artificially intelligent cardiac solutions for the point-of-care devices made by US ultrasound imaging company Terason.
This is an example of how Israeli medical data helps research into diseases. Ben Gurion University’s Dr Yair Zlotnik has used the database of Israeli Health company Clalit to analyze patients with both Parkinson’s and fibromyalgia. The findings could lead to new treatment options.
Researchers at Tel Aviv University and Sheba Medical Center have linked metastatic melanoma progression to a patient’s lipid (fatty acid) metabolism. Skin cancer is more sensitive to immune T-cells if the lipid metabolism is high. The scientists say the discovery can lead to new therapies.
The US FDA has granted accelerated approval to XPOVIO for the treatment of resistant or relapsed multiple myeloma. XPOVIO (Selinexor) was developed by Karyopharm Therapeutics, established by Israel’s Dr. Sharon Shacham,.and based in Newton MA.